Data gathered: September 15
Alternative Data for Altimmune
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 87 | Sign up | Sign up | Sign up |
| Webpage traffic | 68,000 | Sign up | Sign up | Sign up |
| Google Trends | 39 | Sign up | Sign up | Sign up |
| Patents | 23 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,135 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 39,200 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,751 | Sign up | Sign up | Sign up |
| Twitter Mentions | 130 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 79 | Sign up | Sign up | Sign up |
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
| Price | $3.59 |
| Target Price | Sign up |
| Volume | 2,060,000 |
| Market Cap | $321M |
| Year Range | $3.38 - $7.71 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Altimmune appoints Richardson as Chief Commercial OfficerSeptember 15 - Thefly.com |
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial OfficerSeptember 15 - GlobeNewswire |
|
Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the FirmSeptember 15 - GlobeNewswire |
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 14 - GlobeNewswire |
|
 |
Altimmune (NASDAQ:ALT) vs. Savara (NASDAQ:SVRA) Critical AnalysisSeptember 12 - ETF Daily News |
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTSeptember 12 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 5,000 | 30,000 | -25,000 | -22M | -23M | -0.270 |
| Q1 '25 | 5,000 | 0 | 5,000 | -20M | -20M | -0.260 |
| Q4 '24 | 5,000 | 33,000 | 5,000 | -23M | -23M | -0.330 |
| Q3 '24 | 5,000 | 37,000 | 5,000 | -23M | -23M | -0.321 |
| Q2 '24 | 5,000 | 61,000 | -56,000 | -25M | -25M | -0.350 |
Insider Transactions View All
| Sohn Catherine A. filed to buy 1,000 shares at $5.8. March 18 '25 |
| WEAVER GREGORY L filed to buy 10,000 shares at $5.2. March 14 '25 |
| Drutz David filed to sell 41,958 shares at $6.9. August 20 '24 |
| Drutz David filed to sell 55,524 shares at $6.9. August 20 '24 |
| Drutz David filed to buy 29,785 shares at $2.9. August 15 '23 |
Similar companies
Read more about Altimmune (ALT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Altimmune?
The Market Cap of Altimmune is $321M.
What is the current stock price of Altimmune?
Currently, the price of one share of Altimmune stock is $3.59.
How can I analyze the ALT stock price chart for investment decisions?
The ALT stock price chart above provides a comprehensive visual representation of Altimmune's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Altimmune shares. Our platform offers an up-to-date ALT stock price chart, along with technical data analysis and alternative data insights.
Does ALT offer dividends to its shareholders?
As of our latest update, Altimmune (ALT) does not offer dividends to its shareholders. Investors interested in Altimmune should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Altimmune?
Some of the similar stocks of Altimmune are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.